Eli Lilly Invests $3.83 Billion in Vaccine Firms; FDA Panel Backs Updated COVID Shot for XFG Variant
AJMC reported on August 9 that Eli Lilly has acquired three vaccine development companies for $3.83 billion, signaling major investment in the sector. An FDA advisory panel voted to recommend updated COVID-19 vaccines targeting the XFG variant for the 2026-2027 season. These developments shape the upcoming immunization landscape.
Related stories
FDA Clears Four Updated COVID Vaccines for 2026-27 Season · Infectious disease
SW.2 Leads COVID Variant Mix in Late August; Test Positivity Remains Low · Infectious disease
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “Upcoming 2026-2027 Vaccine Season: Deals, Data, and an FDA Vote.” Browse more stories.